Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

BACKGROUND: A recent phase II clinical trial (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan trial and an identical trial in Japan (RADAR/JAPAN)) showed that the endothelin A receptor antagonist atrasentan lowers albuminuria, blood pressure, cholesterol, hemo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Prev Cardiol
Main Authors: Schievink, Bauke, de Zeeuw, Dick, Smink, Paul A, Andress, Dennis, Brennan, John J, Coll, Blai, Correa-Rotter, Ricardo, Hou, Fan Fan, Kohan, Donald, Kitzman, Dalane W, Makino, Hirofumi, Parving, Hans-Henrik, Perkovic, Vlado, Remuzzi, Giuseppe, Tobe, Sheldon, Toto, Robert, Hoekman, Jarno, Lambers Heerspink, Hiddo J
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735387/
https://ncbi.nlm.nih.gov/pubmed/26229089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047487315598709
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados